Vitrolife : 6 March 2024, Carnegie Healthcare Seminar Stockholm

Carnegie Healthcare Seminar 2024

Patrik Tolf, CFO

2024-03-06

Mission

Be the leading global partner in reproductive health,

striving for better treatment

outcomes for patients

Global presence in

125

markets

Employees

• 1,100

Sales in 2023

3,512 MSEK

2

Significant market opportunity in reproductive health

Successful treatment outcomes ~33% ***

1 in 6	134 M	Access and	5-7%
people globally is	babies born annually**	affordability	estimated cycle
affected by infertility*	< 1% via IVF		growth

3	*Source: World Health Organization **Source: United Nations ***ESHRE European mean pregnancy rate in 2019

Corporate Strategy Vitrolife Group

Market	Growth	Labour and			Patient
megatrends	in demand	skills shortage	Consolidation	Regionalisation	empowerment

Our values

Integrity

Quality

Vision with a purpose

"Enable people to fulfil the dream of having a healthy baby"

Mission

"Be the leading global partner in reproductive health, striving for better treatment outcomes for patients"

Long-term growth and profit objectives

Annual organic	EBITDA	Net debt/
revenue growth in
local currencies	margin	EBITDA
>10%	>33%	<3

Innovation

Collaboration

1.		2.		3.		4.
Own the platform		Innovate to expand		Accelerate growth		Optimise go-to-
connecting products		leadership		in key markets		market model
and services

5.

Drive operational

excellence

4	Ensure sustainability in everything we do

Financial highlights 2023

Sales

3,512 MSEK

(3,234 MSEK) +10% in SEK

EBITDA

1,136 MSEK

Margin 32.3% (32.5%)

Organic growth*		Gross margin
+5%		56.3%
In local currencies		(55.0%)
Operating cash flow		Earnings per share**
757 MSEK		3.31 SEK
(636 MSEK)		(2.91 SEK)

* Organic growth excluding discontinued business (Covid testing and GPDx China)

5 ** Adjusted for impairment charge of SEK 4,300 million

Sales and growth per geographical segment, 2023

Organic growth*

Sales (MSEK)

Share of total sales

Americas	EMEA	APAC	Total
-4%	+6%	+15%	+5%

1 159	1 286	1 066	3 512
33%	37%	30%

6

* Organic growth in local currencies

Q&A

DISCLAIMER

This presentation contains estimates and forward-looking statements, which reflect the Management's current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there is no assurance that these statements are correct or will be achieved. The most important strategic and operative risks regarding Vitrolife Group's business and field are described in the Management report, in the Annual Report. These are primarily constituted by macro-economic risks, operational risks and financial risks.